CN114829400B - 抗pd-l1抗体 - Google Patents

抗pd-l1抗体 Download PDF

Info

Publication number
CN114829400B
CN114829400B CN202080064795.6A CN202080064795A CN114829400B CN 114829400 B CN114829400 B CN 114829400B CN 202080064795 A CN202080064795 A CN 202080064795A CN 114829400 B CN114829400 B CN 114829400B
Authority
CN
China
Prior art keywords
seq
amino acid
antigen binding
acid sequence
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080064795.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114829400A (zh
Inventor
史蒂夫·福尔摩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentesa Pharmaceuticals Uk Ltd
Original Assignee
Sentesa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentesa Pharmaceuticals Uk Ltd filed Critical Sentesa Pharmaceuticals Uk Ltd
Publication of CN114829400A publication Critical patent/CN114829400A/zh
Application granted granted Critical
Publication of CN114829400B publication Critical patent/CN114829400B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080064795.6A 2019-07-15 2020-07-15 抗pd-l1抗体 Active CN114829400B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1910138.5 2019-07-15
GBGB1910138.5A GB201910138D0 (en) 2019-07-15 2019-07-15 Anti-pd-l1 antibodies
PCT/EP2020/070065 WO2021009267A1 (en) 2019-07-15 2020-07-15 Anti-pd-l1 antibodies

Publications (2)

Publication Number Publication Date
CN114829400A CN114829400A (zh) 2022-07-29
CN114829400B true CN114829400B (zh) 2024-05-17

Family

ID=67700332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080064795.6A Active CN114829400B (zh) 2019-07-15 2020-07-15 抗pd-l1抗体

Country Status (8)

Country Link
US (1) US20220356255A1 (https=)
EP (1) EP3999113A1 (https=)
JP (1) JP7653408B2 (https=)
KR (1) KR20220057526A (https=)
CN (1) CN114829400B (https=)
CA (1) CA3143957A1 (https=)
GB (1) GB201910138D0 (https=)
WO (1) WO2021009267A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023016706A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CN116917322A (zh) * 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof
CN108948193A (zh) * 2017-05-18 2018-12-07 珠海市丽珠单抗生物技术有限公司 针对tim-3的抗体分子,抗原结合片段及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof
CN108948193A (zh) * 2017-05-18 2018-12-07 珠海市丽珠单抗生物技术有限公司 针对tim-3的抗体分子,抗原结合片段及其医药用途

Also Published As

Publication number Publication date
GB201910138D0 (en) 2019-08-28
CA3143957A1 (en) 2021-01-21
KR20220057526A (ko) 2022-05-09
EP3999113A1 (en) 2022-05-25
CN114829400A (zh) 2022-07-29
JP7653408B2 (ja) 2025-03-28
US20220356255A1 (en) 2022-11-10
WO2021009267A1 (en) 2021-01-21
JP2022541192A (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
CN110606891B (zh) 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途
CN111153995B (zh) Nkg2a抗体及其制备方法和应用
CN111434688A (zh) Cd73抗体及其制备方法和应用
BR112021005868A2 (pt) Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
CA3027204A1 (en) Pd-l1-specific antibodies and methods of using the same
US20240309087A1 (en) Anti-cd112r antibody and use thereof
CN111196854A (zh) Ox40抗体及其制备方法和应用
CN117916263B (zh) 抗tigit抗体及其用途
CN110172099B (zh) 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
TW202202529A (zh) 一種雙特異性抗體及其用途
CN116209680A (zh) 与人CD3ε结合的新型人抗体
CN110461875B (zh) 结合light的抗原结合分子
CN115010810A (zh) 抗ctla-4抗体及其应用
CN108948193B (zh) 针对tim-3的抗体分子,抗原结合片段及其医药用途
CN112105391B (zh) 抗-bcma抗体及其用途
CN114829400B (zh) 抗pd-l1抗体
CN117355540A (zh) 抗cd137抗体和使用方法
CN110546164A (zh) 特异性结合cd40的抗体及其用途
TWI839395B (zh) 靶向cd137的抗體及其使用方法
WO2025162161A1 (zh) 特异性结合pd-1的单克隆抗体及其医药用途
TW202415677A (zh) 抗TNFα抗體及組合物
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN110272489B (zh) 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途
WO2024078558A1 (zh) 抗cd100抗体及其用途
KR20230168598A (ko) 항-tigit 항체 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240220

Address after: Cheshire

Applicant after: Sentesa Pharmaceuticals (UK) Ltd.

Country or region after: United Kingdom

Address before: London

Applicant before: CAPELLA BIOSCIENCE Ltd.

Country or region before: United Kingdom

GR01 Patent grant
GR01 Patent grant